SynthesisBMC cardiovascular disorders2026
Prognostic value of systemic inflammation response index in patients with myocardial infarction: a systematic review and meta-analysis.
Synthesis in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immuno-inflammatory-metabolic interactions in cardiovascular diseases: a review from basic mechanisms to clinical translation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesThis study evaluates the prognostic value of the systemic inflammation response index (SIRI) in myocardial infarction (MI) patients.
methodsPubMed, Embase, Web of Science, and Cochrane were used to search literature through January 2026, focusing on mortality and major adverse cardiovascular events (MACE) as outcomes. Risk ratios (RR) and 95% confidence intervals (CI) were used for data synthesis. Sensitivity and subgroup analyses assessed result stability and identified potential sources of heterogeneity. For results with publication bias, the trim-and-fill method was used to assess its impact on the results.
resultsThirteen studies involving 16,054 MI patients were included. Higher SIRI linked with an increased risk of mortality (RR: 2.73; 95% CI: 1.82, 4.10; P < 0.00001) and MACE (RR: 1.54; 95% CI: 1.37, 1.73; P < 0.00001) in MI patients. Sensitivity analysis confirmed the stability of SIRI as a predictor for both mortality and MACE. Subgroup analysis indicated that the SIRI cut-off value was the primary contributor to the significant heterogeneity observed in mortality and MACE.
conclusionsSIRI can effectively predict mortality and MACE in MI patients, identifying those at high risk early for targeted intervention. Larger, multicenter, prospective cohort studies are required to further evaluate its prognostic value in MI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.